Enhanced immune responses of mice inoculated recombinant adenoviruses expressing GP5 by fusion with GP3 and/or GP4 of PRRS virus.
Porcine reproductive and respiratory syndrome (PRRS) is one of the most important causes of economic losses of the swine industry. PRRS virus (PRRSV) infection poses a challenge to current vaccination strategies. In this study, three replication-defective adenovirus recombinants expressing fusion protein GP3-GP5, GP4-GP5, or GP3-GP4-GP5 were developed as potential vaccine against PRRSV in a mouse model. Six groups of BALB/c mice (24mice per group) were inoculated subcutaneously twice at 2-week intervals with above mentioned recombinants and other adenoviruses expressing single GP3, GP4, or GP5 protein. The results showed that the mice inoculated with recombinant adenoviruses developed PRRSV-specific antibodies, cellular immune response by 2 weeks post-boost-immunization. However, mice immunized with recombinant adenoviruses rAd-GP3-GP5, rAd-GP4-GP5, and rAd-GP3-GP4-GP5 developed significantly higher titers of neutralizing antibodies to PRRSV and produced stronger lymphocyte proliferation responses compared to mice immunized with rAd-GP3, rAd-GP4 or rAd-GP5 alone. It was also found that mice immunized with rAd-GP3-GP5 and rAd-GP3-GP4-GP5 were primed for significant higher levels of anti-PRRSV CTL responses than mice immunized with rAd-GP3 and rAd-GP5. These findings suggested that the recombinant adenoviruses expressing fusion proteins GP3-GP5 or GP3-GP4-GP5 might be an attractive candidate vaccine for preventing PRRSV infection.
Key Laboratory of Animal Diseases Diagnostic and Immunology, College of Veterinary Medicine, Nanjing Agricultural University, Ministry of Agriculture, Nanjing 210095, China.
Wenming
W
Jiang
Ping
P
Jiang
Xianwei
X
Wang
Yufeng
Y
Li
Yijun
Y
Du
Xinglong
X
Wang
D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D049109:Cell Proliferation; D003602:Cytotoxicity, Immunologic; D005260:Female; D007117:Immunization, Secondary; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D019316:Porcine respiratory and reproductive syndrome virus / Q000235:genetics* / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D015678:Viral Structural Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D011993:Recombinant Fusion Proteins; D015678:Viral Structural Proteins; D014765:Viral Vaccines